Transition from "Evidence Generation" as a one-time project to a continuous, automated business process that secures long-term market access.
Market access decisions are won or lost on the quality of your evidence architecture. We built our RWE Engine to give pharma and biotech leaders a permanent, automated advantage — from payer simulation to living regulatory dossiers — so your data works as hard as your science does.
Implementing a secure, GxP-compliant data lake that ingests de-identified EMR data, claims data, and patient registries.
The Tech Stack: Use of FHIR (Fast Healthcare Interoperability Resources) APIs for seamless data exchange.
AI-driven simulations that predict how a payer (like NICE in the UK or ICER in the US) will react to specific clinical endpoints.
Early-stage sensitivity analysis to identify which "Real World" outcomes (e.g., reduction in hospital readmissions) will have the highest impact on pricing.
A "Living Dossier" system that automatically updates clinical evidence packages as new real-world data flows in, facilitating faster label expansions.
Reduction in months between regulatory approval and inclusion on national formularies.
Maintenance of premium pricing levels over a 3-year period vs. historical erosion.
Your growth journey starts with a conversation. Connect with our senior partners today to align our expertise in Business Model Innovation and Digital Transformation with your strategic topline priorities.